The Pediatric Praziquantel Consortium Announces Positive Phase III Results for Arpraziquantel To Treat Schistosomiasis
The Pediatric Praziquantel Consortium completes its pivotal clinical Phase III trial of arpraziquantel – a potential new treatment option for the estimated 50 million preschool-aged children with schistosomiasis.